[
  {
    "question": "Pseudorosette what's the dx",
    "option_a": "(Ependymoma) is correct because the hallmark pseudorosette formation is most characteristic of ependymomas. Other tumor types such as astrocytomas, medulloblastomas, or oligodendrogliomas do not typically exhibit this pattern, making them less likely diagnoses in this context.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "Ependymomas are glial tumors that arise from ependymal cells which line the ventricular system. A distinguishing histopathological feature is the formation of perivascular pseudorosettes, where tumor cells are arranged around blood vessels with fibrillary processes interposed. The development of pseudorosettes in ependymomas reflects the tumor cells' attempt to organize around blood vessels, a pattern not seen in other gliomas. These tumors can occur anywhere along the ventricular system or within the spinal cord and vary in aggressiveness depending on the grade. Patients with ependymomas may present with signs of increased intracranial pressure (if intracranial) or localized neurological deficits (if spinal). The formation of pseudorosettes on histology is a key feature that assists in confirming the diagnosis and differentiating it from other pediatric or adult brain tumors. Differential diagnoses include astrocytomas, medulloblastomas (which may display Homer Wright rosettes), and oligodendrogliomas. Histopathological evaluation along with immunohistochemical markers (e.g., GFAP positivity) helps in confirming the diagnosis of ependymoma. The mainstay of treatment for ependymomas is maximal safe surgical resection, which often results in substantial symptom relief and decreased recurrence rates. Adjuvant radiotherapy is considered, particularly for higher-grade or incompletely resected tumors. In pregnant or lactating patients, surgical timing is planned carefully (typically during the second trimester) and radiotherapy is usually delayed until after delivery unless absolutely necessary. Option a (Ependymoma) is correct because the hallmark pseudorosette formation is most characteristic of ependymomas. Other tumor types such as astrocytomas, medulloblastomas, or oligodendrogliomas do not typically exhibit this pattern, making them less likely diagnoses in this context. 1. Pseudorosettes are a classic histological feature of ependymomas. 2. Maximal safe resection remains the cornerstone of ependymoma management. 3. Differentiating pseudorosettes from true rosettes (e.g., Homer Wright rosettes in medulloblastomas) is key in neuropathology. Recent research underlines the importance of molecular characterization in ependymomas, which may in future guide more individualized treatments. Standard management remains surgical resection followed by risk-adapted radiotherapy, with ongoing trials exploring targeted therapies for refractory cases.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has left temporal lobe GBM with clear mass effect on imaging asking what is next step, patient has rt side weakness and confusion",
    "option_a": "(Steroid) is correct because it directly targets vasogenic edema which causes the mass effect in GBM. Surgical decompression is important but typically follows stabilization with steroids. Osmotic agents like mannitol are reserved for acute situations of raised intracranial pressure in emergencies, while antiepileptics treat seizures but do not relieve edema.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuro-oncology",
    "explanation": "In patients with high-grade brain tumors such as glioblastoma multiforme (GBM), vasogenic edema is a frequent and dangerous complication. The use of corticosteroids\u2014most commonly dexamethasone\u2014is fundamental to reduce cerebral edema and alleviate mass effect. In this case, the patient\u2019s neurological deficits (right\u2010side weakness, confusion) are secondary to the edema produced by the tumor mass effect. GBMs disrupt the blood-brain barrier, leading to extravasation of fluid (vasogenic edema) in the brain parenchyma. This increased intracranial pressure can cause focal neurological deficits and risk of herniation. Dexamethasone helps restore the blood-brain barrier integrity and decreases capillary permeability, thereby reducing swelling. Neurological symptoms such as confusion and focal weakness correlate with the location and extent of edema. Rapid administration of steroids can improve symptoms by decreasing intracranial pressure, making them an immediate priority before definitive surgical or oncologic treatments. Imaging (CT/MRI) is used to evaluate tumor size and edema. Differential diagnoses for mass effect include brain abscess, other neoplasms causing mass effect, or hemorrhagic infarcts; however, the known diagnosis of GBM along with radiographic features confirms the cause. First-line management for symptomatic vasogenic edema is high-dose corticosteroids (e.g., dexamethasone). This treatment is initiated to improve neurologic symptoms and stabilize the patient prior to surgical intervention. Second-line measures might include surgical decompression in cases refractory to medical management. In pregnancy, dexamethasone is considered when the benefits outweigh the risks, with evidence suggesting careful dosing to minimize potential fetal effects while still controlling maternal intracranial pressure. Option A (Steroid) is correct because it directly targets vasogenic edema which causes the mass effect in GBM. Surgical decompression is important but typically follows stabilization with steroids. Osmotic agents like mannitol are reserved for acute situations of raised intracranial pressure in emergencies, while antiepileptics treat seizures but do not relieve edema. 1. Dexamethasone is the steroid of choice in brain tumors due to its potent anti-edema effects and minimal mineralocorticoid activity. 2. Rapid improvement in neurological symptoms after steroid initiation can confirm edema as the cause of symptoms. 3. Always consider steroid therapy as a temporizing measure before definitive tumor management. Recent guidelines from neuro-oncology societies and the NCCN continue to recommend corticosteroids for management of symptomatic cerebral edema in brain tumors. Studies emphasize that steroid therapy is essential for acute management, bridging the time to surgical, radiotherapeutic, or chemotherapeutic interventions.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "A 57-year-old male patient with renal cell carcinoma brought to the ED with confusion and seizure. Brain MRI shows single mass with vasogenic edema. Which of the following is the most appropriate treatment?",
    "option_a": "Surgical removal",
    "option_b": "Intrathecal chemotherapy",
    "option_c": "Whole brain radiation",
    "option_d": "Biological treatments",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Brain metastases often present in patients with systemic cancer, such as renal cell carcinoma (RCC). When a solitary brain metastasis is identified, especially in a patient with new-onset seizures and confusion, management typically includes surgical removal of the lesion to alleviate mass effect and obtain a tissue diagnosis. Metastatic lesions from RCC tend to be well-circumscribed and may create significant vasogenic edema causing neurological symptoms. The mass effect varies with lesion size and location. Removal of the lesion can reduce edema and prevent further neurological compromise. Symptoms like seizures and confusion directly correlate with the presence of a space-occupying lesion in the brain. A solitary metastasis, particularly from RCC which can be hypervascular, is best managed surgically if the patient is an appropriate operative candidate. Brain MRI is the modality of choice. Differential diagnoses can include primary brain tumors, abscesses, or hemorrhagic lesions. However, in a patient with a known history of RCC, a solitary brain mass with surrounding edema is most consistent with a metastasis. For a solitary brain metastasis, the first-line treatment is surgical excision, which reduces mass effect and provides histopathological confirmation. Adjuvant therapies such as stereotactic radiosurgery or whole-brain radiation therapy (WBRT) may follow. Although intrathecal chemotherapy and biological treatments are available for other conditions, they are not considered first-line for a single brain metastasis. In special circumstances like pregnancy, surgical management remains preferred if the timing and fetal maturity permit intervention, though radiation might be deferred or modified to minimize fetal exposure. A: Surgical removal is correct because a solitary and accessible brain metastasis from RCC is best managed surgically. B: Intrathecal chemotherapy is not standard for brain metastases. C: Whole brain radiation is generally reserved for multiple metastases or as an adjuvant after surgery. D: Biological treatments are not first-line in this setting. 1. In patients with a solitary brain metastasis from RCC, surgical resection not only alleviates symptoms but also allows for histological confirmation. 2. Always assess the patient\u2019s overall condition and systemic disease burden before planning surgery. 3. Postoperative adjuvant radiotherapy is typically considered to manage microscopic disease. Recent guidelines emphasize that surgical resection is the cornerstone of treatment for solitary brain metastases when feasible, especially in patients with controlled systemic disease. Emerging research suggests improved outcomes with combined modality treatment including surgical resection and targeted radiotherapy.",
    "exam_year": "2023",
    "exam_type": "Part I",
    "image_url": "page_26.png"
  },
  {
    "question": "Case scenario for patient with brain tumor. MRI brain report: Focal lesion with peripheral enhancement and hypointense central core. Pathology report showed highly vascular proliferation with atypia and central necrosis. Which of the following is the most likely diagnosis?",
    "option_a": "Glioblastoma multiform.",
    "option_b": "Meningioma.",
    "option_c": "Astrocytoma.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "The imaging finding of a focal lesion with peripheral enhancement and a hypointense central core, together with a pathology report demonstrating highly vascular proliferation with atypia and central necrosis, is characteristic of glioblastoma multiforme (GBM). GBM is a high-grade (WHO Grade IV) astrocytic tumor that is notorious for pseudopalisading necrosis, microvascular proliferation, and a disrupted blood-brain barrier leading to peripheral contrast enhancement. The central necrosis reflects rapid tumor growth outstripping its blood supply. Patients typically present with rapid neurological deterioration, seizures, or focal deficits corresponding to the tumor's location. The described radiographic and pathological features directly correlate with the aggressive nature of GBM. Diagnosis is based on brain MRI findings such as ring enhancement and confirmation via biopsy. Differential diagnoses include brain abscess (which may also show ring enhancement but lacks the pathologic features of GBM) and metastasis (usually in patients with a known primary malignancy). Histopathology differentiates GBM by its necrosis and microvascular proliferation. The standard management for GBM includes maximal safe surgical resection, followed by adjuvant radiotherapy with concurrent and adjuvant temozolomide chemotherapy\u2014the Stupp protocol. For patients who are pregnant, treatment options require multidisciplinary discussion balancing fetal risks; radiotherapy and temozolomide have significant teratogenic risks and may be deferred or modified depending on gestational age. A: Glioblastoma multiforme is correct given the characteristic imaging and pathology findings. B: Meningioma usually presents as an extra-axial mass and is not typically associated with central necrosis. C: Lower-grade astrocytomas lack the rapid growth, necrosis, and microvascular proliferation seen in GBM. 1. GBM is characterized by ring enhancement on imaging due to central necrosis. 2. Histopathology confirming pseudopalisading necrosis and microvascular proliferation is pathognomonic. 3. The aggressive nature of GBM mandates a multimodal treatment approach with surgery, radiation, and chemotherapy. Recent clinical trials and guideline updates continue to support the Stupp protocol as the standard of care for GBM. There is ongoing research into molecular markers and targeted therapies, although these have yet to replace current multimodal treatment strategies.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Pt came he has cyst, his brother has hemangioblastoma, there is family hx his brother and sister?",
    "option_a": "von Hippel-Lindau syndrome",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Von Hippel-Lindau (VHL) syndrome is an autosomal dominant inherited disorder characterized by a predisposition to multiple tumors including hemangioblastomas, particularly in the central nervous system. A family history of hemangioblastomas in siblings strongly suggests VHL syndrome. VHL syndrome results from mutations in the VHL tumor suppressor gene, leading to dysregulation of hypoxia-inducible factors and consequent upregulation of angiogenic factors. This mechanism promotes the formation of highly vascular tumors such as hemangioblastomas, retinal angiomas, and cysts in multiple organs. Patients often present with CNS hemangioblastomas causing neurological deficits, retinal angiomas that can lead to vision loss, and cystic lesions in organs like the pancreas or kidneys. A positive family history is a key clinical clue in the diagnosis of VHL syndrome. Diagnosis is based on clinical criteria, imaging studies, and genetic testing. Differentiation includes sporadic hemangioblastoma versus those occurring as part of VHL syndrome. Other conditions may include neurofibromatosis; however, the specific combination of family history and tumor types points to VHL. Management of VHL syndrome requires surveillance for the various associated tumors. Regular CNS imaging, abdominal imaging, and ophthalmologic evaluation are recommended. Early detection allows for timely intervention such as surgical removal of symptomatic lesions. In pregnancy or lactation, surveillance is maintained with imaging modalities that avoid radiation when possible (e.g., MRI) and decisions about surgical timing are made on a case-by-case basis with a multidisciplinary team. A: Von Hippel-Lindau syndrome is correct since the family history and clinical presentation are highly suggestive of this inherited condition. Other options would be incorrect as they do not account for the genetic and familial aspects of the syndrome. 1. A positive family history of hemangioblastomas is a hallmark of VHL syndrome. 2. VHL is a multisystem disorder requiring comprehensive lifelong surveillance. 3. Genetic counseling is essential as VHL syndrome has an autosomal dominant pattern with variable penetrance. Recent advancements in genetic testing and surveillance guidelines have improved early detection and management outcomes in VHL syndrome. Multidisciplinary care models continue to be emphasized in the latest clinical practice guidelines to optimize patient outcomes.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Pic of meningioma ask about pathology (They did not mention meningioma in Qs).",
    "option_a": "Roussate",
    "option_b": "Pseudorossate",
    "option_c": "Psammoma bodies",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-oncology",
    "explanation": "Meningiomas are typically benign, extra-axial tumors arising from arachnoidal cap cells. They are known for their characteristic histopathological features that include whorled patterns and calcifications. On histological examination, many meningiomas demonstrate concentric calcified structures known as psammoma bodies. These form due to progressive calcification of the whorled mesenchymal cells. This is a hallmark finding in several subsets of meningioma, especially the meningothelial type. Patients with meningiomas may present with headaches, seizures, or focal neurological deficits depending on tumor location. Radiologically, they are seen as dural-based, extra-axial masses sometimes with a 'dural tail' sign. The presence of psammoma bodies on pathology further supports the diagnosis when correlating with imaging and clinical data. Diagnosing meningioma involves neuroimaging (MRI or CT) to assess tumor location and features, followed by histological examination after surgical biopsy or resection. Differential diagnoses on imaging include schwannomas, metastatic lesions, and dural-based lymphoma. Histopathology demonstrating psammoma bodies helps differentiate meningiomas from these other entities. The primary treatment for meningiomas is surgical resection, which is often curative in cases of complete excision. Adjuvant radiotherapy may be considered for atypical or malignant cases or if resection is incomplete. In the context of pregnancy and lactation, surgical timing and anesthetic management must be carefully planned to minimize fetal risk, with many cases managed in the second trimester if urgent intervention is required. Option A ('Roussate') is not a recognized histologic term for meningiomas. Option B ('Pseudorossate') is more commonly associated with ependymoma, which features perivascular pseudorosettes. Option C ('Psammoma bodies') is the correct answer because it accurately reflects the common calcific deposits seen in meningiomas. 1. Meningiomas frequently occur in middle-aged women. 2. The 'dural tail' sign on MRI is a useful radiologic hint. 3. Psammoma bodies are a key histologic feature that can help confirm the diagnosis. Recent guidelines and studies continue to support the role of surgical resection as the mainstay therapy for meningiomas with histopathologic confirmation, including the identification of psammoma bodies. Advances in neurosurgical techniques have improved outcomes even in challenging locations.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "A 57-year-old male patient with renal cell carcinoma brought to the ED with confusion and seizure. Brain MRI shows with vasogenic edema. Which of the following is the most appropriate treatment?",
    "option_a": "Surgical removal",
    "option_b": "Whole brain radiation",
    "option_c": "Chemotherapy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Brain metastases from renal cell carcinoma (RCC) present a unique therapeutic challenge due to their relative radioresistance and potential for significant vasogenic edema. Vasogenic edema surrounding metastatic lesions results from the disruption of the blood-brain barrier by tumor invasion. RCC metastases tend to be hypervascular, which can lead to local hemorrhage and significant edema. A 57-year-old male with RCC presenting with confusion and seizures is highly suggestive of a brain metastatic process. The symptoms related to raised intracranial pressure and focal neurological deficits necessitate prompt intervention. Evaluation generally begins with brain MRI, which is sensitive for detecting metastases and associated edema. Differential diagnoses include primary brain tumors (glioblastoma, astrocytoma) and other metastatic lesions (from lung, melanoma). The history of RCC strongly favors metastatic disease. The standard of care for a solitary, accessible brain metastasis\u2014especially in RCC\u2014is surgical removal, since RCC is relatively radioresistant. First-line management involves surgical resection to provide both diagnostic confirmation and alleviation of mass effect. Stereotactic radiosurgery (SRS) may also be considered for small lesions or in patients who are poor surgical candidates. Whole brain radiation therapy is generally reserved for multiple metastases. In pregnant or lactating patients, surgical timing necessitates a multidisciplinary approach involving maternal-fetal medicine to minimize fetal risks. Option A (Surgical removal) is correct as it addresses both tissue diagnosis and symptomatic relief in a solitary, accessible metastasis. Option B (Whole brain radiation) is less effective given RCC\u2019s radioresistance and is typically not first-line for a solitary lesion. Option C (Chemotherapy) is generally ineffective for brain metastases due to the limited ability of agents to cross the blood-brain barrier. 1. RCC brain metastases are often hemorrhagic and produce significant vasogenic edema. 2. Surgical resection improves both survival and quality of life in patients with solitary metastases. 3. Always consider the patient\u2019s overall systemic disease burden when planning treatment. Recent studies emphasize the benefit of aggressive local control through surgery (or SRS) for RCC brain metastases. Multi-modality management including targeted therapies is under investigation, and updated NCCN guidelines recommend individualized treatment planning based on lesion characteristics and patient factors.",
    "exam_year": "2024",
    "exam_type": "Part I",
    "image_url": "page_13.png"
  },
  {
    "question": "What is the pathology of Ependymoma.",
    "option_a": "Roussate",
    "option_b": "Pseudorossate",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Ependymomas are neuroepithelial tumors that arise from ependymal cells lining the ventricular system and the central canal of the spinal cord. Their histopathology is distinct and often includes rosette formations. The characteristic finding in ependymoma is the presence of perivascular pseudorosettes \u2013 tumor cells arranged around blood vessels with an intervening clear zone, rather than true lumen formation. This pattern is a diagnostic clue when evaluating these tumors histologically. Ependymomas can occur both intracranially (commonly in children within the posterior fossa) and in the spinal cord (often in young adults). The presence of pseudorosettes on pathology helps differentiate them from other glial tumors. The diagnosis of ependymoma involves neuroimaging (MRI) to localize the lesion, usually followed by histopathological analysis. The differential includes astrocytomas, which lack the pseudorosette formation, and other small round cell tumors. Immunohistochemical stains can further aid in diagnosis. The primary treatment for ependymomas is maximal safe surgical resection. In cases of incomplete resection, adjuvant radiotherapy may be recommended. In pregnancy and lactation, surgical intervention is considered based on symptom severity and gestational age, with careful coordination among neurosurgery and obstetrics specialists. Option A ('Roussate') is not associated with ependymoma. Option B ('Pseudorossate') \u2013 representing perivascular pseudorosettes \u2013 is the correct answer as it accurately describes the typical histopathological pattern seen in ependymomas. 1. Perivascular pseudorosettes are a key histologic feature of ependymomas. 2. These tumors can be located in both the brain and spinal cord. 3. Complete surgical resection is the mainstay of treatment. Recent research has focused on the molecular characterization of ependymomas, leading to improved prognostic stratification and tailored treatment approaches. Advances in neuroimaging and surgical techniques continue to enhance outcomes.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "MRI showed intramedullary, ill defined, non-enhancing lesion, what' the diagnosis.",
    "option_a": "Astrocytoma.",
    "option_b": "Ependymoma",
    "option_c": "Meningioma",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Intramedullary spinal cord tumors include a variety of neoplasms such as astrocytomas, ependymomas, and, less commonly, hemangioblastomas. Their imaging characteristics help narrow the differential diagnosis. Astrocytomas in the spinal cord typically present as infiltrative, ill-defined lesions with variable or minimal contrast enhancement due to their diffuse growth pattern. Their non-enhancing nature on MRI reflects the tumor\u2019s relatively lower vascularity compared to other intramedullary tumors. Patients with spinal cord astrocytomas often present with slowly progressive motor weakness, sensory deficits, and sometimes pain due to the infiltrative nature of the tumor. The ill-defined margins and non-enhancing characteristics are important clues on imaging. The diagnostic workup involves MRI as the primary imaging modality. Differential diagnoses include ependymomas, which usually manifest as well-circumscribed, enhancing lesions centered in the central canal, and meningiomas, which are typically extramedullary and enhance vividly. The clinical presentation and imaging findings together help guide the diagnosis. Management primarily involves surgical intervention aimed at maximal safe resection, although complete resection may be challenging due to the infiltrative nature of astrocytomas. Radiotherapy may serve as an adjuvant therapy, particularly in higher-grade lesions. In pregnant or lactating patients, treatment plans require a careful balance between maternal benefit and fetal risk, often deferring non-emergent surgery until after delivery if possible. Option A (Astrocytoma) is correct because these tumors are typically ill-defined and may not show robust contrast enhancement on MRI. Option B (Ependymoma) is usually well-circumscribed and shows significant enhancement. Option C (Meningioma) is typically extramedullary and has a different imaging profile. 1. Intramedullary astrocytomas are generally infiltrative with ill-defined margins on MRI. 2. Contrast enhancement patterns on MRI are crucial for differentiating among spinal cord tumors. 3. Early diagnosis is important to prevent irreversible neurological deficits. Recent literature emphasizes the role of advanced MRI techniques in differentiating spinal cord tumors. Emerging molecular markers are also being investigated to improve prognostication and guide individualized therapy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient known case of breast cancer came with ataxia, nystagmus.",
    "option_a": "Anti-RI",
    "option_b": "Anti-Yo",
    "option_c": "Anti-Hu",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Paraneoplastic neurological syndromes occur when an immune response to neoplastic tissue cross\u2010reacts with antigens in the nervous system. Paraneoplastic cerebellar degeneration (PCD) is one such syndrome in which antibodies target cerebellar Purkinje cells, leading to cerebellar dysfunction. Anti\u2010Yo antibodies are directed against intracellular antigens found in Purkinje cells. In patients with breast (and gynecologic) cancers, the immune system may generate these antibodies which then cross-react with cerebellar tissue, leading to degeneration and subsequent clinical findings. This process is T-cell mediated with a secondary antibody response, and recent research continues to support the immunologic basis of PCD. Patients typically present with symptoms of cerebellar dysfunction \u2013 most notably gait ataxia, dysmetria, dysarthria and nystagmus. In a patient with a known history of breast cancer, the development of ataxia and nystagmus strongly suggests a paraneoplastic process involving anti\u2010Yo antibodies. The evaluation generally includes serologic tests for paraneoplastic antibodies (e.g., anti\u2010Yo, anti\u2010Hu, anti\u2010Ri), brain MRI to rule out structural lesions or direct metastases, and CSF analysis. Differential diagnoses include metastatic cerebellar lesions (which often enhance differently), stroke, or cerebellar degeneration from other causes. Management centers on treating the underlying malignancy and controlling the immune response. First-line treatment includes oncologic therapy (surgery, chemotherapy, or radiotherapy, tailored to the patient) and immunomodulatory approaches (corticosteroids, IVIG, or plasmapheresis). In pregnancy and lactation, treatment decisions are more challenging; targeted therapies and immunomodulation must consider fetal safety, often necessitating a multidisciplinary approach. Option A (Anti\u2010RI) is more typically associated with paraneoplastic opsoclonus\u2010myoclonus syndrome. Option C (Anti\u2010Hu) is classically related to small cell lung cancer and sensory neuronopathy. Option B (Anti\u2010Yo) is correctly identified as the most frequent antibody in breast\u2010cancer\u2013associated paraneoplastic cerebellar degeneration. 1. Always consider a paraneoplastic syndrome in a cancer patient with subacute cerebellar symptoms. 2. Anti\u2010Yo antibodies are the most common in breast and ovarian cancer\u2013related PCD. 3. Early recognition and treatment of the underlying cancer and immune reaction may improve outcomes. Recent guidelines stress early antibody testing in suspected paraneoplastic syndromes and advocate for a combined oncologic and immunotherapy approach. Advances in immunomodulatory therapy are being explored, although definitive controlled trials remain limited.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with only skull and Dural Mets what to do:",
    "option_a": "Chest ct",
    "option_b": "Mri abdomen",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Paraneoplastic neurological syndromes occur when an immune response to neoplastic tissue cross\u2010reacts with antigens in the nervous system. Paraneoplastic cerebellar degeneration (PCD) is one such syndrome in which antibodies target cerebellar Purkinje cells, leading to cerebellar dysfunction. Anti\u2010Yo antibodies are directed against intracellular antigens found in Purkinje cells. In patients with breast (and gynecologic) cancers, the immune system may generate these antibodies which then cross-react with cerebellar tissue, leading to degeneration and subsequent clinical findings. This process is T-cell mediated with a secondary antibody response, and recent research continues to support the immunologic basis of PCD. Patients typically present with symptoms of cerebellar dysfunction \u2013 most notably gait ataxia, dysmetria, dysarthria and nystagmus. In a patient with a known history of breast cancer, the development of ataxia and nystagmus strongly suggests a paraneoplastic process involving anti\u2010Yo antibodies. The evaluation generally includes serologic tests for paraneoplastic antibodies (e.g., anti\u2010Yo, anti\u2010Hu, anti\u2010Ri), brain MRI to rule out structural lesions or direct metastases, and CSF analysis. Differential diagnoses include metastatic cerebellar lesions (which often enhance differently), stroke, or cerebellar degeneration from other causes. Management centers on treating the underlying malignancy and controlling the immune response. First-line treatment includes oncologic therapy (surgery, chemotherapy, or radiotherapy, tailored to the patient) and immunomodulatory approaches (corticosteroids, IVIG, or plasmapheresis). In pregnancy and lactation, treatment decisions are more challenging; targeted therapies and immunomodulation must consider fetal safety, often necessitating a multidisciplinary approach. Option A (Anti\u2010RI) is more typically associated with paraneoplastic opsoclonus\u2010myoclonus syndrome. Option C (Anti\u2010Hu) is classically related to small cell lung cancer and sensory neuronopathy. Option B (Anti\u2010Yo) is correctly identified as the most frequent antibody in breast\u2010cancer\u2013associated paraneoplastic cerebellar degeneration. 1. Always consider a paraneoplastic syndrome in a cancer patient with subacute cerebellar symptoms. 2. Anti\u2010Yo antibodies are the most common in breast and ovarian cancer\u2013related PCD. 3. Early recognition and treatment of the underlying cancer and immune reaction may improve outcomes. Recent guidelines stress early antibody testing in suspected paraneoplastic syndromes and advocate for a combined oncologic and immunotherapy approach. Advances in immunomodulatory therapy are being explored, although definitive controlled trials remain limited.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A brain tumor and histology of pseudorosette:",
    "option_a": "Ependymoma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Paraneoplastic neurological syndromes occur when an immune response to neoplastic tissue cross\u2010reacts with antigens in the nervous system. Paraneoplastic cerebellar degeneration (PCD) is one such syndrome in which antibodies target cerebellar Purkinje cells, leading to cerebellar dysfunction. Anti\u2010Yo antibodies are directed against intracellular antigens found in Purkinje cells. In patients with breast (and gynecologic) cancers, the immune system may generate these antibodies which then cross-react with cerebellar tissue, leading to degeneration and subsequent clinical findings. This process is T-cell mediated with a secondary antibody response, and recent research continues to support the immunologic basis of PCD. Patients typically present with symptoms of cerebellar dysfunction \u2013 most notably gait ataxia, dysmetria, dysarthria and nystagmus. In a patient with a known history of breast cancer, the development of ataxia and nystagmus strongly suggests a paraneoplastic process involving anti\u2010Yo antibodies. The evaluation generally includes serologic tests for paraneoplastic antibodies (e.g., anti\u2010Yo, anti\u2010Hu, anti\u2010Ri), brain MRI to rule out structural lesions or direct metastases, and CSF analysis. Differential diagnoses include metastatic cerebellar lesions (which often enhance differently), stroke, or cerebellar degeneration from other causes. Management centers on treating the underlying malignancy and controlling the immune response. First-line treatment includes oncologic therapy (surgery, chemotherapy, or radiotherapy, tailored to the patient) and immunomodulatory approaches (corticosteroids, IVIG, or plasmapheresis). In pregnancy and lactation, treatment decisions are more challenging; targeted therapies and immunomodulation must consider fetal safety, often necessitating a multidisciplinary approach. Option A (Anti\u2010RI) is more typically associated with paraneoplastic opsoclonus\u2010myoclonus syndrome. Option C (Anti\u2010Hu) is classically related to small cell lung cancer and sensory neuronopathy. Option B (Anti\u2010Yo) is correctly identified as the most frequent antibody in breast\u2010cancer\u2013associated paraneoplastic cerebellar degeneration. 1. Always consider a paraneoplastic syndrome in a cancer patient with subacute cerebellar symptoms. 2. Anti\u2010Yo antibodies are the most common in breast and ovarian cancer\u2013related PCD. 3. Early recognition and treatment of the underlying cancer and immune reaction may improve outcomes. Recent guidelines stress early antibody testing in suspected paraneoplastic syndromes and advocate for a combined oncologic and immunotherapy approach. Advances in immunomodulatory therapy are being explored, although definitive controlled trials remain limited.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "NF type 1 patient who presented with syncopal attacks and there is a lateral ventricular mass what is the tumor:",
    "option_a": "SEGA",
    "option_b": "Central neurocytoma",
    "option_c": "Choroid plexus papilloma",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Subependymal giant cell astrocytomas (SEGAs) are benign tumors that typically occur in patients with tuberous sclerosis complex (TSC) and are usually located near the foramen of Monro along the walls of the lateral ventricles. Even though the stem mentions NF type 1, the clinical scenario of a lateral ventricular mass causing syncopal episodes (likely via obstructive hydrocephalus) is most consistent with SEGA \u2013 a classic finding in TSC. SEGAs develop from subependymal cells lining the ventricles due to mutations in TSC1 or TSC2 genes that lead to dysregulation of the mTOR pathway. This results in abnormal cell growth and formation of a benign but potentially obstructive neoplasm. While NF type 1 is associated with other central nervous system tumors (e.g., optic pathway gliomas), SEGAs are hallmark lesions of tuberous sclerosis. Patients with tuberous sclerosis typically exhibit a combination of dermatologic findings (such as ash-leaf spots, shagreen patches), seizures, and cognitive challenges. A tumor near the foramen of Monro can lead to obstructive hydrocephalus and consequent symptoms like syncopal attacks. Despite the mention of NF type 1 in the stem, the lateral ventricular mass strongly favors the diagnosis of a SEGA. Diagnosis is primarily by neuroimaging. MRI of the brain reveals a lesion located near the foramen of Monro with features such as calcifications and slow growth. Differential diagnoses include central neurocytoma (typically seen in young adults) and choroid plexus papilloma (more common in children and associated with CSF overproduction), but the clinical context and association with a neurocutaneous syndrome help narrow the diagnosis to SEGA. The primary treatment for SEGAs is surgical resection, especially when the tumor is symptomatic or causing obstructive hydrocephalus. In patients who are not optimal surgical candidates or in cases of progressive tumor growth, mTOR inhibitors such as everolimus have been approved as an alternative therapy. For pregnant or lactating patients, surgical timing must be carefully coordinated, and mTOR inhibitors are generally contraindicated during pregnancy due to teratogenic risks; similar caution should be exercised during lactation. A multidisciplinary approach involving neurosurgery, neurology, and maternal\u2013fetal medicine is essential in managing these cases. Option A (SEGA) is the best choice given the lateral ventricular location and the clinical presentation of obstructive symptoms. Options B (Central neurocytoma) and C (Choroid plexus papilloma) are less consistent with the full clinical picture and neurocutaneous correlations. Option D is not provided. Even though the stem states NF type 1, the described tumor location and clinical features align best with SEGA, a tumor typically seen in tuberous sclerosis. \u2022 Always correlate radiologic findings with the patient\u2019s neurocutaneous stigmata. \n\u2022 SEGAs, though benign, can cause serious complications like obstructive hydrocephalus and require careful management. \n\u2022 mTOR inhibitors are a valuable alternative in inoperable cases but are contraindicated in pregnancy. Recent guidelines and studies have supported the use of everolimus for managing SEGAs in TSC, demonstrating significant tumor regression. Surgical resection remains the mainstay for symptomatic lesions. Close monitoring with serial imaging is recommended, and the management plan should incorporate special considerations in the context of pregnancy and lactation to minimize fetal and neonatal risks.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A brain tumor with characteristic cells encircling each other called psammoma bodies",
    "option_a": "Meningioma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Meningiomas are common, typically benign tumors arising from the meningothelial (arachnoid cap) cells of the dura mater. They are often well-defined, extra-axial lesions that can cause symptoms due to local mass effect. Meningiomas originate from arachnoid cap cells and are characterized by a whorled pattern of cell growth. A key histopathologic finding is the presence of psammoma bodies, which are concentrically laminated calcific deposits. These calcifications are common in certain variants and help in histologic diagnosis. Patients with meningiomas may present with headaches, seizures, or focal neurological deficits depending on the tumor location. The slow-growing nature of these tumors often leads to insidious clinical presentation. Psammoma bodies are a classic diagnostic clue on microscopic examination, confirming the diagnosis when imaging is suggestive. Diagnosis is typically made with neuroimaging, particularly MRI with contrast which can show a dural-based mass with a characteristic enhancement. Differential diagnoses include schwannomas, metastatic lesions, and dural-based lymphomas. A definitive diagnosis is made through histopathological examination after surgical resection or biopsy. First-line management for symptomatic meningiomas is surgical resection, with the goal of complete removal. In cases where complete resection is not feasible or in higher grade lesions, adjuvant radiotherapy is recommended. During pregnancy, clinical management requires balancing maternal neurological stability with fetal safety; imaging may be deferred or limited, and surgery is planned with multidisciplinary input if urgent intervention is needed. Option A (Meningioma) is correct because the description of psammoma bodies is pathognomonic for meningioma. Other options (not provided) would not typically feature the classic concentric calcifications related to whorled cell arrangements seen in meningiomas. 1. Meningiomas are more common in middle-aged women. 2. Psammoma bodies, while not exclusive, are a strong histologic marker for meningiomas. 3. They are usually slow-growing, which often results in insidious onset of symptoms. Recent studies emphasize the role of advanced imaging and minimally invasive surgical techniques, including stereotactic radiosurgery, in the management of meningiomas. Updated guidelines also recommend a tailored approach for lesions found during pregnancy to minimize risks to both mother and fetus.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with renal cell carcinomal, retinal hemangioblastoma, cerebellar hemangioblastoma; what is the Dx?",
    "option_a": "Von Hiplle Lindau",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by mutations in the VHL tumor suppressor gene, leading to a predisposition for various tumor types including hemangioblastomas and renal cell carcinoma. The VHL gene normally regulates hypoxia-inducible factors (HIF). A mutation results in the stabilization of HIF, leading to abnormal upregulation of angiogenic factors and subsequent neovascularization. This predisposes patients to develop highly vascular tumors such as retinal and cerebellar hemangioblastomas as well as clear cell renal cell carcinomas. Clinically, VHL disease should be suspected in patients who develop a constellation of tumors at a young age, including retinal hemangioblastomas, cerebellar hemangioblastomas, and renal cell carcinomas. Early diagnosis allows for effective surveillance and timely intervention as these tumors can be life-threatening if not managed appropriately. Diagnosis is based on family history, clinical findings, and confirmatory genetic testing for VHL gene mutations. Imaging modalities such as MRI for CNS lesions and CT scans for renal lesions are essential. Differential diagnoses include other hereditary tumor syndromes such as tuberous sclerosis, but the distinct tumor profile of VHL\u2014especially the combination of hemangioblastomas and renal cell carcinoma\u2014helps differentiate it. Management involves regular surveillance with periodic imaging (MRI/CT) and clinical examinations. Surgical resection is indicated for symptomatic or growing tumors. In patients with VHL who are pregnant or lactating, careful monitoring is required; non-contrast MRIs are generally considered safe during pregnancy and lactation, and interventions are timed to balance tumor control with fetal safety. Option A is correct because the clinical scenario\u2014renal cell carcinoma combined with retinal and cerebellar hemangioblastomas\u2014is classic for VHL disease. Other differential options would not typically present with this specific constellation of tumors. 1. VHL disease can manifest with multiple, often asymptomatic, tumors, necessitating systematic surveillance. 2. The combination of retinal and cerebellar hemangioblastomas with renal cell carcinoma is highly suggestive of VHL. 3. Early genetic counseling and family screening are essential. The latest guidelines advocate for genetic testing and periodic surveillance protocols starting in childhood. There is growing evidence supporting minimally invasive surgical techniques and the use of targeted therapies in managing renal lesions and CNS hemangioblastomas in VHL patients.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Child with proptosis his mother has also proptosis and light brown dots in the neck:",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder characterized by multiple caf\u00e9-au-lait spots, neurofibromas, and a predisposition to various benign and malignant tumors. NF1 results from a mutation in the NF1 gene, which codes for neurofibromin, a protein that negatively regulates the RAS/MAPK pathway. Loss of neurofibromin function leads to increased cellular proliferation and tumor formation. The presence of caf\u00e9-au-lait spots and Lisch nodules (iris hamartomas) are hallmark clinical features. The described case\u2014a child with proptosis along with a mother exhibiting similar findings and the presence of light brown caf\u00e9-au-lait spots\u2014is classic for NF1. Proptosis in NF1 can often be attributed to optic pathway gliomas, a common manifestation of this disorder. NF1 is diagnosed using the NIH diagnostic criteria which include the presence of six or more caf\u00e9-au-lait spots, neurofibromas, freckling in the axillary or inguinal regions, optic gliomas, Lisch nodules, and a positive family history. Differential diagnoses include NF2 (which typically presents with bilateral vestibular schwannomas), tuberous sclerosis (ash leaf spots, cortical tubers), Sturge-Weber syndrome (port-wine stains), and McCune-Albright syndrome (caf\u00e9-au-lait spots with irregular borders and endocrine abnormalities). Management is primarily supportive and focuses on regular monitoring for tumor development and complications. Optic pathway gliomas, if progressive or vision-threatening, may require chemotherapy or surgical intervention. In pregnant patients, NF1 is associated with an increased risk for certain complications, so careful prenatal monitoring is recommended. Regular ophthalmologic, dermatologic, and neurologic evaluations form the backbone of management. The marked answer (NF1) is correct. It is supported by the presence of caf\u00e9-au-lait spots, proptosis likely due to optic glioma, and a positive family history. Other differentials such as NF2, Sturge-Weber, tuberous sclerosis, or McCune-Albright do not match the clinical profile provided in the question. 1. NF1 commonly presents with caf\u00e9-au-lait spots and can have ocular involvement like optic gliomas. 2. A positive family history is a strong diagnostic clue in NF1. 3. Regular monitoring is crucial to identify complications early. Recent research emphasizes the importance of early diagnosis and multidisciplinary management in NF1. Updated guidelines recommend routine surveillance for optic pathway gliomas and other neurofibromatous complications, with emerging targeted therapies for specific manifestations of the disease.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with headache and bilateral 6th nerve palsy with papilledema, red mass seen from the nostril MRI cystic lesion arising from the clivus, Dx:",
    "option_a": "cordoma",
    "option_b": "osteohesitosis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Chordomas are rare malignant tumors thought to arise from remnants of the notochord. They typically occur in the axial skeleton, with common sites including the clivus and sacrococcygeal region. Chordomas develop from embryonic notochordal remnants. They are characterized histologically by physaliphorous (bubble-bearing) cells and a myxoid stromal background. Their location at the skull base (clivus) accounts for cranial nerve involvement in many patients. Patients with chordomas of the clivus may present with headache, cranial nerve deficits (such as 6th nerve palsy leading to diplopia), and signs of increased intracranial pressure (papilledema). The description of a red mass visible from the nostril suggests an extension into the nasopharyngeal region, which can occur with clival chordomas. MRI is the imaging modality of choice, revealing a midline, often lobulated lesion with both solid and cystic components. Differential diagnoses include chondrosarcoma (which may appear similar on imaging but tends to be off-midline and has different histologic features) and other skull base lesions. Definitive diagnosis is established by biopsy and subsequent histopathological analysis with immunohistochemical staining. The mainstay of treatment is en bloc surgical resection with the aim of complete tumor removal, often followed by adjuvant radiotherapy (proton beam therapy being a preferred modality due to its precision). In pregnancy, management of chordomas is challenging; surgical intervention may be postponed if the tumor is indolent and the pregnancy is far from term, while in urgent cases, a multidisciplinary team must plan interventions to minimize fetal risk. Radiotherapy is typically deferred during pregnancy unless absolutely necessary and with fetal shielding. Option A (Chordoma) is correct. The lesion's origin from the clivus, the clinical signs of raised intracranial pressure via bilateral 6th nerve palsy and papilledema, along with the mass visible from the nostril, all point towards a clival chordoma. Option B (osteohesitosis) does not correspond to any recognized entity that matches this clinical and radiologic profile. 1. Chordomas typically arise in midline structures such as the clivus and sacrum. 2. Cranial nerve involvement, particularly of the abducens nerve (CN VI), is a key clinical sign for clival lesions. 3. Surgical resection is the cornerstone of therapy, with adjuvant radiotherapy playing a significant role. Recent advancements in surgical techniques and the utilization of proton beam therapy have improved local control rates and reduced morbidity in patients with chordomas. Ongoing research focuses on targeted molecular therapies and improving outcomes in complex anatomical regions such as the skull base.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with CNS tumor pathology showed Fried egg appearance, What is the treatment:",
    "option_a": "Chemotherapy",
    "option_b": "Radiotherapy",
    "option_c": "Gamma knife surgery",
    "option_d": "Debulking Surgery",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuro-oncology",
    "explanation": "The 'fried egg' appearance on histopathology is a classic description of oligodendroglioma. Oligodendrogliomas are primary brain tumors arising from oligodendrocytes and are most often found in the cerebral hemispheres, particularly in the frontal lobes. Oligodendrogliomas display cells with round nuclei and clear cytoplasm (an artifact of formalin fixation), creating a 'fried egg' look. Genetically, these tumors often harbor a 1p/19q co-deletion and IDH mutation, which have prognostic and therapeutic implications. The tumor\u2019s relatively slow growth and well-defined margins make it amenable to surgical resection. Patients with oligodendrogliomas may present with seizures, focal neurological deficits, or signs of raised intracranial pressure depending on tumor size and location. The frontal lobe involvement often correlates with personality changes and executive dysfunction. Diagnosis is based on neuroimaging (MRI typically shows a heterogeneous mass with calcifications) and definitive histopathological analysis. Differential diagnoses include astrocytomas (which do not show the 'fried egg' appearance), mixed oligoastrocytomas, and glioblastoma. Molecular testing for 1p/19q co-deletion and IDH mutation further supports the diagnosis. The first-line treatment is maximal safe surgical resection (debulking surgery), which reduces mass effect and provides tissue for definitive histological diagnosis. Adjuvant therapy, including radiotherapy and chemotherapy (such as the PCV regimen or temozolomide), is often considered based on tumor grade and molecular markers. In pregnancy, surgery is generally considered safe with proper precautions, while radiotherapy is typically delayed until after the first trimester or postpartum due to fetal risks. Lactating mothers need a risk\u2013benefit assessment as certain chemotherapeutic agents and radiation can be contraindicated. Option A (Chemotherapy) is not the initial treatment but may be used adjuvantly. Option B (Radiotherapy) is generally an adjunct following resection rather than the primary treatment. Option C (Gamma knife surgery) is inappropriate for oligodendrogliomas, which are best managed with resection. Option D (Debulking Surgery) is the current standard initial approach, making it the correct answer. 1) The 'fried egg' appearance is pathognomonic for oligodendroglioma on histology. 2) Maximal safe resection is essential not only for symptom relief but also for accurate tumor grading and guiding adjuvant therapy. 3) Molecular markers such as 1p/19q co-deletion have significant prognostic and therapeutic implications. Recent guidelines emphasize the role of surgical resection followed by tailored adjuvant therapy based on molecular profiling. Studies have shown that patients with 1p/19q co-deleted tumors respond well to combined radiotherapy and chemotherapy, but the initial management remains surgical.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with GBM MRI showed increased edema and mass effect; what is the next?",
    "option_a": "Keppra",
    "option_b": "Steroid",
    "option_c": "chemotherapy",
    "option_d": "Radiotherapy",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "In glioblastoma multiforme (GBM), peritumoral edema is common and contributes significantly to symptoms due to the mass effect and increased intracranial pressure. GBM disrupts the blood-brain barrier, leading to vasogenic edema surrounding the tumor. The resulting increase in intracranial pressure manifests clinically as headaches, nausea, and altered consciousness. Steroids, particularly dexamethasone, reduce capillary permeability, which decreases edema rapidly. Patients with GBM may present with worsening neurological symptoms due to edema. The increased mass effect can exacerbate focal deficits and signs of raised intracranial pressure such as papilledema. Assessment is based on neuroimaging (MRI showing a ring-enhancing lesion with central necrosis and surrounding edema) and clinical evaluation. Differential diagnoses include other high-grade gliomas, brain abscesses, or metastases; however, the rapid clinical decline and typical imaging features of GBM help differentiate it. The first-line management for symptomatic edema in GBM is the administration of corticosteroids (commonly dexamethasone), which provides rapid relief by reducing vasogenic edema. This is an urgent therapeutic step while planning definitive treatment (surgical resection, radiotherapy, and chemotherapy with temozolomide). In pregnant patients, dexamethasone is used cautiously due to possible fetal effects, but its benefits in reducing life-threatening edema usually outweigh the risks. During lactation, potential steroid exposure should be balanced against the necessity of treatment, and temporary cessation of breastfeeding may be considered. Option A (Keppra) is used for seizure prophylaxis but does not address edema. Option B (Steroid) directly alleviates the edema and mass effect, making it the correct next step. Options C (Chemotherapy) and D (Radiotherapy) are components of long-term management rather than immediate relief of edema. 1) Dexamethasone is the cornerstone for managing tumor-associated cerebral edema in GBM. 2) Rapid control of edema is essential to prevent herniation and further neurological compromise. 3) Always consider the need for seizure prophylaxis in these patients, even though steroids are the priority for edema. Current clinical guidelines continue to support the use of dexamethasone for the management of peritumoral edema in GBM, with ongoing research into optimizing dosing to minimize steroid-related side effects while effectively reducing intracranial pressure.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Female patient has papilledema, signs of ICP, MRI showed frontal mass; what is the next step?",
    "option_a": "Debulking surgery",
    "option_b": "Sterotactic Biopsy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "A patient presenting with papilledema, clinical signs of increased intracranial pressure (ICP), and an MRI showing a frontal mass raises concern for a space-occupying lesion that requires prompt intervention. The presence of a frontal mass can obstruct normal cerebrospinal fluid dynamics and directly increase intracranial pressure. Papilledema is a hallmark sign of raised ICP due to swelling of the optic disc. Symptoms such as headache, nausea, visual disturbances, and potential focal neurological deficits correlate with increased ICP. In cases where the mass is accessible, resection not only alleviates pressure but also provides a tissue diagnosis. The diagnostic workup includes neuroimaging (MRI with contrast) to define the lesion's size, location, and characteristics. Differential diagnoses include meningioma, high-grade gliomas, and metastases. A stereotactic biopsy is considered when lesions are located in deep or eloquent areas; however, in a frontal mass with raised ICP, urgent debulking may be preferred. Given the symptomatic raised ICP and the accessibility of a frontal lesion, the first-line treatment is debulking surgery to rapidly reduce mass effect and obtain a definitive diagnosis. Preoperative administration of corticosteroids is often used to temporarily reduce edema. In pregnancy, surgical intervention is feasible with appropriate fetal monitoring and timing, while radiological studies are carefully considered. Lactating patients are managed similarly, with attention to minimizing exposure to anesthetic agents and postoperative medications that may transfer into breast milk. Option A (Debulking Surgery) is appropriate as it directly reduces mass effect, alleviates ICP, and provides tissue diagnosis. Option B (Stereotactic Biopsy) is more suited for lesions in deep, inoperable locations and would not adequately address the raised ICP in this scenario. The absence of other options means that surgical resection is the prudent choice. 1) In patients with signs of increased ICP and an accessible mass, early surgical intervention is crucial to prevent catastrophic outcomes. 2) Always use steroids preoperatively to manage edema, especially in the setting of raised ICP. 3) Debulking not only relieves symptoms but also facilitates definitive histopathological diagnosis. Recent neurosurgical guidelines affirm that in cases of symptomatic intracranial masses with raised ICP, particularly those in non-eloquent areas like the frontal lobe, maximum safe resection is the treatment of choice. Studies continue to support the integration of surgical resection with adjunct therapies based on precise tumor characterization, including in special populations such as pregnant and lactating women.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]